This job aid assists the clinical provider with contraceptive considerations for transgender, nonbinary, and gender diverse (TNGD) patients assigned female at birth (AFAB). Special considerations are given for contraception for people on concurrent testosterone use, potential side effects, and menstrual suppression. Contraceptive methods are listed according to menstrual suppression, possibility of spotting/bleeding, cramping, breast tissue tenderness, and self-disclosure.
The Centers for Disease Control and Prevention (CDC) recently released Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention on June 6, 2024. This report is the first to outline the CDC's recommendation for the use of doxycycline postexposure prophylaxis (doxy PEP).
Learn more by watching our recorded DIALS from November 2023. Dr. Hilary Reno's slides outline the evidence base for doxy PEP.
In this DIALS, recorded on 11/27/23, Dr. David Turok and Dr. Hilary Reno discussed emerging research that supports emergency contraception and post-exposure prophylaxis for sexually transmitted infections, including HIV. Studies have shown that PEP and EC are appropriate for prophylaxis following unprotected intercourse. Additionally, doxy PEP shows promise as a preventive measure for gonorrhea, chlamydia, and syphilis.
